Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
Laura JimbuOana MesarosCristian PopescuAlexandra NeagaIulia BerceanuDelia DimaMihaela GamanMihnea T ZdrengheaPublished in: Pharmaceuticals (Basel, Switzerland) (2021)
Checkpoint inhibitors were a major breakthrough in the field of oncology. In September 2014, based on the KEYNOTE-001 study, the Food and Drug Administration (FDA) approved pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced or unresectable melanoma. Up until now, seven PD-1/PD-ligand(L)-1 inhibitors are approved in various solid cancers and hundreds of clinical studies are currently ongoing. In hematology, PD-1 inhibitors nivolumab and pembrolizumab were approved for the treatment of relapsed/refractory (R/R) classic Hodgkin lymphoma, and later pembrolizumab was approved for R/R primary mediastinal large B-cell lymphoma. In acute myeloid leukemia (AML), the combination of hypomethylating agents and PD-1/PD-L1 inhibitors has shown promising results, worth of further investigation, while other combinations or single agent therapy have disappointing results. On the other hand, rather than in first line, these therapies could be useful in the consolidation or maintenance setting, for achieving minimal residual disease negativity. Furthermore, an interesting application could be the use of PD-1/PD-L1 inhibitors in the post allogeneic hematopoietic stem cell transplantation relapse. There are several reasons why checkpoint inhibitors are not very effective in treating AML, including the characteristics of the disease (systemic, rapidly progressive, and high tumor burden disease), low mutational burden, and dysregulation of the immune system. We here review the results of PD-1/PD-L1 inhibition in AML and discuss their potential future in the management of this disease.
Keyphrases
- drug administration
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- hodgkin lymphoma
- acute lymphoblastic leukemia
- dna damage
- diffuse large b cell lymphoma
- cell cycle
- palliative care
- cell proliferation
- squamous cell carcinoma
- stem cells
- radiation therapy
- mesenchymal stem cells
- small molecule
- risk assessment
- current status
- binding protein
- open label
- young adults